Preferred Name |
dapagliflozin |
|
Synonyms |
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol |
|
ID |
http://purl.bioontology.org/ontology/MESH/C529054 |
|
altLabel |
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol Farxiga (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol Forxiga BMS-512148 BMS512148 BMS 512148 |
|
cui |
C5433403 C2353949 C3700957 C2353950 C2353951 |
|
HM |
D005960 D001559 |
|
Inverse of RB |
1ULL0QJ8UC 0 |
|
isa | ||
LT |
TRD |
|
Mapped to | ||
MDA |
20080521 |
|
MeSH Frequency |
1280 |
|
MMR |
20210503 |
|
notation |
C529054 |
|
PA |
D000077203 |
|
prefLabel |
dapagliflozin |
|
SC |
1 |
|
SRC |
Drug News Perspect 2007 Dec;20(10):645 |
|
TERMUI |
T720183 T720182 T001092461 T828433 T001092460 T720771 T720772 T720184 |
|
TH |
NLM (2020) NLM (2008) FDA SRS (2013) USAN (19XX) INN (19XX) NLM (2013) NLM (2014) |
|
tui |
T109 T121 |
Create mapping